CNS stimulant
Methylphenidate hydrochloride
Brand names: Ritalin, Concerta XL, Equasym XL, Medikinet XL, Xaggitin
Adult dose
Dose: Specialist initiation. Initial 5mg BD-TDS, titrate weekly. MR preparations 18–54mg OD. Brand-specific — formulations not interchangeable
Route: PO
Frequency: OD-TDS
Clinical pearls
- First-line for ADHD (children ≥5y, adults). CD2 controlled drug (Concerta XL CD2; Ritalin CD2). Brand-specific
- Cardiac history + BP/HR before initiation; growth monitoring in children
Contraindications
- Symptomatic cardiovascular disease
- Moderate-severe hypertension
- Hyperthyroidism
- Concurrent MAOI / within 14 days
- Glaucoma
- Phaeochromocytoma
- Severe depression / psychosis
Side effects
- Reduced appetite
- Insomnia
- Tachycardia
- Hypertension
- Anxiety
- Tics
- Psychosis
- Cardiomyopathy (rare)
- Priapism (rare)
Interactions
- MAOIs (avoid)
- Sympathomimetics
- Antihypertensives
- Antiepileptics
Monitoring
- BP
- HR
- Weight
- Height
- Mental state
Reference: BNF; NICE NG87; https://bnf.nice.org.uk/drugs/methylphenidate-hydrochloride/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF